Free Trial
→ Tesla Execs are Freaking Out (From Angel Publishing) (Ad) Free PODD Stock Alerts

Insulet (PODD) Stock Forecast & Price Target

Insulet logo
$266.58 +4.59 (+1.75%)
(As of 11/20/2024 ET)
Compare

Insulet - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 15 Analyst Ratings
Sell
0
Hold
3
Buy
12

Based on 15 Wall Street analysts who have issued ratings for Insulet in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 3 have given a hold rating, and 12 have given a buy rating for PODD.

Consensus Price Target

$253.27
-4.99% Downside
According to the 15 analysts' twelve-month price targets for Insulet, the average price target is $253.27. The highest price target for PODD is $317.00, while the lowest price target for PODD is $200.00. The average price target represents a forecasted downside of -4.99% from the current price of $266.58.
Get the Latest News and Ratings for PODD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Insulet and its competitors.

Sign Up

PODD Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24		1 Month Ago
10/23/23 to 10/22/24		3 Months Ago
8/24/23 to 8/23/24		1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
11 Buy rating(s)
13 Buy rating(s)
11 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
6 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$253.27$242.29$229.93$254.80
Forecasted Upside-4.99% Downside2.40% Upside24.26% Upside36.76% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
This Bull Market Indicator called NVDA at $116 (Ad)

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

PODD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PODD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Insulet Stock vs. The Competition

TypeInsuletMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside-4.99% Downside26,931.60% Upside9.83% Upside
News Sentiment Rating
Positive News

See Recent PODD News
Neutral News
Positive News
Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/11/2024Barclays
3 of 5 stars		 Boost TargetEqual Weight ➝ Equal Weight$220.00 ➝ $234.00-15.16%
11/11/2024Morgan Stanley
3 of 5 stars		 Boost TargetOverweight ➝ Overweight$234.00 ➝ $317.00+18.28%
11/8/2024BTIG Research
2 of 5 stars		M. Thibault
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetBuy ➝ Buy$260.00 ➝ $270.00-1.61%
11/6/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating		L. Hambright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageOutperform$300.00+24.32%
10/14/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$213.00 ➝ $260.00+12.57%
10/1/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$250.00 ➝ $275.00+18.98%
9/25/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$236.00 ➝ $269.00+12.26%
9/17/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$230.00 ➝ $285.00+21.85%
8/9/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetNeutral ➝ Neutral$211.00 ➝ $223.00+22.14%
6/10/2024OTR Global
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingPositive ➝ Mixed
5/30/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$235.00+36.43%
5/10/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$255.00 ➝ $260.00+46.48%
5/7/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradePeer Perform ➝ Outperform$200.00+13.38%
2/23/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$190.00 ➝ $225.00+19.78%
2/5/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetHold ➝ Hold$163.00 ➝ $208.00+7.39%
12/21/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeNeutral ➝ Outperform$180.00 ➝ $238.00+14.44%
10/16/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating		M. Kratky
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingOutperform
10/16/2023Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOutperform$184.00+35.83%
8/24/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$365.00 ➝ $295.00+56.48%
8/9/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform ➝ Outperform$350.00 ➝ $300.00+30.61%
8/9/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight ➝ Overweight$375.00 ➝ $330.00+38.46%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:56 AM ET.


PODD Forecast - Frequently Asked Questions

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Insulet is $253.27, with a high forecast of $317.00 and a low forecast of $200.00.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PODD shares.

According to analysts, Insulet's stock has a predicted downside of -4.99% based on their 12-month stock forecasts.

Insulet has been rated by research analysts at Barclays, BTIG Research, Canaccord Genuity Group, Citigroup, Morgan Stanley, Piper Sandler, Raymond James, and Sanford C. Bernstein in the past 90 days.

Analysts like Insulet less than other "medical" companies. The consensus rating score for Insulet is 2.80 while the average consensus rating score for "medical" companies is 2.80. Learn more on how PODD compares to other companies.

Related Companies
Today's Ratings
Top Rated Stocks
More Ratings Tools

This page (NASDAQ:PODD) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners
Unveiled: NVIDIA’s "Secret Royalty" Program
Did you know that there's an investment that will give you the opportunity to collect "royalties" every time N...
Behind the Markets | Sponsored